Alumis stock tumbles 55% after lupus drug trial misses goals
Alumis Inc. (ALMS) shares dropped 55% after its Phase 2b LUMUS trial for envudeucitinib in lupus failed primary and secondary endpoints. The trial enrolled 408 patients but showed improvements only in a subgroup with high interferon gene signature (IFNGS-high). The drug was well-tolerated, and the company plans to discuss Phase 3 development for this subgroup with regulators. Alumis remains on track to submit a New Drug Application for psoriasis in Q4 2026.
How this was made
The 30-second read
Why it matters
The failed Phase 2b trial undermines near‑term valuation but the subgroup data may guide a more targeted Phase 3.
Market read
The announcement drives a sharp sell‑off in ALMS and could influence peer biotech valuations.
What to watch
Potential regulatory engagement for a focused Phase 3 could mitigate long‑term impact.
Background
Alumis Inc. (NASDAQ:ALMS) is a clinical‑stage biotech developing TYK2 inhibitors for autoimmune diseases.
Ticker impact
Phase 2b LUMUS trial missed primary and secondary endpoints, causing a 55% share drop.
Expect continued downside pressure; price could test $0.30 support.
First‑time disclosure of failed trial in a micro‑cap biotech typically leads to sharp price declines.
Market effects
May weigh on other SLE‑focused biotech stocks and TYK2 inhibitor pipeline companies.
Limited to US biotech sector; no broader regional effect.
Low global relevance beyond niche biotech investors.
Counterpoint
If the IFNGS‑high subgroup shows strong response, a niche upside could emerge on future data.
Key entities
- companyAlumis Inc.
Biopharma developing envudeucitinib for SLE and psoriasis.
